Literature DB >> 26561587

Chemotherapy regimen checks performed by pharmacists contribute to safe administration of chemotherapy.

Shinya Suzuki1, Alexandre Chan2,3, Hisanaga Nomura1, Philip E Johnson4, Kazushi Endo5,6, Shinichiro Saito1.   

Abstract

Background Computerized provider order entry (CPOE) has been developed and implemented within cancer center hospitals nationwide in Japan. To ensure that high-quality services are routinely provided by oncology pharmacists, this study was designed to evaluate the interventions through reviewing the orders that are generated by CPOE. Methods The objective of this retrospective chart review was to evaluate how pharmacists contributed to safe cancer treatment using paper-based pharmacy records. Data were collected from a total of 35,062 chemotherapy regimens for 18,515 outpatients between January and December 2013. Results Of these 35,062 chemotherapy regimens, the rate of pharmacists' interventions was 1.1% ( n = 408). Among them, 53.1% (217/408) of the chemotherapy prescriptions were modified due to pharmacist interventions. The reasons for interventions included "changes in the chemotherapy regimen were unclear" in 49.5%, "physicians' prescription errors" (22.0%), "pharmacist suggestions to improve chemotherapy" (15.1%), and "finding differences between physicians' chemotherapy records and their chemotherapy prescriptions" (13.2%). The top three reasons for the 217 prescription modifications due to pharmacist interventions were "finding prescription errors" (34.5%), "reasons for change in the chemotherapy regimen were unclear" (32.7%), and "finding differences between physicians' chemotherapy records and their chemotherapy prescriptions" (28.5%). Conclusion The computer could not evaluate chemotherapy protocols or adjust doses of anticancer medicines according to patients' conditions. Therefore, oncology pharmacists should continue to ensure safe and appropriate administration of cancer chemotherapy.

Entities:  

Keywords:  Pharmacy intervention; cancer chemotherapy; prescription errors

Mesh:

Substances:

Year:  2016        PMID: 26561587     DOI: 10.1177/1078155215614998

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  7 in total

1.  The impact of pharmacist certification on the quality of chemotherapy in Japan.

Authors:  Shinya Suzuki; Hiroomi Sakurai; Kenji Kawasumi; Makoto Tahara; Shinichiro Saito; Kazushi Endo
Journal:  Int J Clin Pharm       Date:  2016-08-29

2.  Clinical and economic impact of pharmacists' intervention in a large volume chemotherapy preparation unit.

Authors:  Ji-Min Han; Young-Mi Ah; Sung Yun Suh; Sun-Hoi Jung; Hyeon Joo Hahn; Seock-Ah Im; Ju-Yeun Lee
Journal:  Int J Clin Pharm       Date:  2016-06-30

3.  Clinical and economic impact of pharmacist interventions on sampled outpatient prescriptions in a Chinese teaching hospital.

Authors:  Zhiwei Bao; Chunmei Ji; Jing Hu; Can Luo; Wentong Fang
Journal:  BMC Health Serv Res       Date:  2018-07-04       Impact factor: 2.655

4.  Impact of outpatient pharmacy interventions on management of thyroid patients receiving lenvatinib.

Authors:  Shinya Suzuki; Ai Horinouchi; Shinya Uozumi; Chihiro Matsuyama; Hayato Kamata; Asumi Kaneko; Masakazu Yamaguchi; Hiroshi Okudera; Makoto Tahara; Toshikatsu Kawasaki
Journal:  SAGE Open Med       Date:  2020-06-12

5.  The Expanding Role of the Oncology Pharmacist.

Authors:  Lisa M Holle; Eve M Segal; Kate D Jeffers
Journal:  Pharmacy (Basel)       Date:  2020-07-25

Review 6.  Effects of Guideline-based Computerized Provider Order Entry Systems on the Chemotherapy Order Process: a Systematic Review.

Authors:  Sougand Setareh; Reza Rabiei; Hamid Reza Mirzaei; Arash Roshanpoor; Mahtab Shaabani
Journal:  Acta Inform Med       Date:  2022-03

7.  Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study.

Authors:  Satoshi Dote; Shoji Itakura; Kohei Kamei; Daiki Hira; Satoshi Noda; Yuka Kobayashi; Tomohiro Terada
Journal:  BMC Cancer       Date:  2018-10-05       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.